# Junta clínica — PT-pseudo_4a2fa7bc3595 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4a2fa7bc3595",
  "pid": "PT-pseudo_4a2fa7bc3595",
  "task": 1,
  "psa": 6.9,
  "age": 67,
  "months": 3,
  "pirads": "5",
  "psad": 0.257,
  "psav": -0.62,
  "psap": 5.6,
  "vol": 26.9,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.84531116,
  "medhx": "Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "metformin, empagliflozin, paracetamol PRN",
  "notes": "PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.",
  "pmhx": [
    "Type 2 diabetes",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "172 cm",
    "bmi": "23.7",
    "bp": "106/78 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (16 pack-yr, quit 2006)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement."
    }
  ],
  "occupation": "retired electrical engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Sleep clinic — suspected obstructive sleep apnoea"
  ],
  "alcohol": "3 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4a2fa7bc3595
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.257 ng/mL²
  - PSA velocity: -0.62 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 26.9 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84531116 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.

Vitals: weight 70 kg, height 172 cm, BMI 23.7, BP 106/78 mmHg, HR 71 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2006).

Chief complaint: Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels.

History: At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities.

Physical examination: DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement.

Patient info: retired electrical engineer; Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 3 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.10 epistemic (95% band 0.35-0.75); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.49: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"
  2. distance 0.60: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  3. distance 0.62: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"

PRECEDENT: DEFER (weighted vote 0.31 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of biopsy is not settled because the guideline makes the decision dependent on the MRI findings, which are not yet fully established. The precedent cited by Expert-Library shows that the decision was DEFER in a similar case, suggesting that the panel variables alone do not determine the outcome.

WHAT WE STILL NEED
The guideline requires information on the MRI findings to determine if a repeat biopsy is warranted. The panel already shows a PI-RADS score of 5, but the guideline requires knowing if the MRI mandates a repeat biopsy to confirm progression. The prior-biopsy status is known as Positive, but the guideline requires knowing the documented grade of the prior biopsy and the number and dates of biopsy sessions to assess progression.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the documented grade and surveillance status from the previous notes, as the EAU guideline requires MRI findings to guide the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy result (Gleason/ISUP), surveillance protocol status, number of biopsy sessions, and planned treatment?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Comparison: compared with an earlier study: new
What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study? The distinct hypointense area occupies the right peripheral zone, spanning from the mid-gland down to the apex, with dimensions of roughly 14 by 11 by 10 mm. Capsular borders remain intact without seminal vesicle infiltration.
psa_trend
What is the serial PSA value trend (rising, flat, or falling)? The serial PSA value trend is rising, with values at "Apr 2023" of "2.3", "Mar 2024" of "4.0", and "Feb 2025" of "6.9".
previous_notes
What is the management context, including the prior biopsy result (Gleason/ISUP), surveillance protocol status, number of biopsy sessions, and planned treatment? The prior biopsy result is not recorded in the text provided. The management context mentions a "first positive prostate biopsy" and "Conservative observation continued during the waiting period."
laboratory_results
What are the full panel results, including free-PSA fraction, renal function, and haemoglobin? PSA is "6.9 ng/mL" on "18 Jan 2025". Free PSA is "1.29 ng/mL" with a "%Free PSA" of "19%". eGFR is ">60 mL/min/1.73m2". Haemoglobin is "15.4 g/dL".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided sufficient context regarding the prior biopsy status and management.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of "5" on the mpMRI.
PSA trend shows a rising trajectory from "2.3" to "6.9" ng/mL.
DRE finding of "Nodus" noted on the initial examination.
Findings that argue AGAINST sampling this patient now:
The previous notes do not document the documented grade (Gleason/ISUP) of the prior biopsy.
The EAU guideline requires further MRI confirmation to determine if a repeat biopsy is warranted.

WHERE THIS LEANS
The findings suggest a high-risk lesion on MRI and a rising PSA, but the decision is stalled pending the documented grade from the prior biopsy and the specific MRI interpretation required by the EAU guideline.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.90 ng/mL over 3 points spanning 22 months; velocity +2.51 ng/mL per year; doubling time about 14 months.
PROJECTION at 6 months: 10.3 ng/mL, conformal 95% band 2.9-35.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.09 epistemic (95% band 0.44-0.79), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.62  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.31  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.57 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—do not fully answer the moderator's questions. Specifically, the previous_notes state the prior biopsy result is "not recorded in the text provided," and the registrar did not explicitly state the number and dates of prior biopsy sessions or surveillance protocol status.

ALIGNMENT WITH THE PANEL
The PANEL-PROTOCOL concluded BIOPSY based on a weighted vote of experts, despite the lack of a documented prior grade in the opened documents. The retrieved evidence supports the need for further investigation due to the PI-RADS 5 and rising PSA trend, aligning with the expert consensus leaning towards biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? This remains unanswered as the previous_notes explicitly state this information is not recorded in the text provided.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? This is also unanswered, as the registrar did not report this information.

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables are the PI-RADS score of 5 on the mpMRI, the rising PSA trend (from 2.3 to 6.9 ng/mL), and the EAU guideline's requirement for MRI confirmation to determine the need for a repeat biopsy. These variables strongly suggest a high-risk scenario requiring further action.

MY SUGGESTION TO THE CHAIR
Given that the necessary documentation regarding the prior biopsy grade and surveillance status is missing from the retrieved records, the decision cannot be definitively made according to the EAU guideline's requirements. Therefore, the case is not ready for a final decision.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the high-risk MRI finding (PI-RADS 5) and the rising PSA trend from 2.3 to 6.9 ng/mL, coupled with the palpable DRE nodus, a biopsy is indicated to establish the documented grade of the prior lesion. The rising PSA trajectory and high PI-RADS score strongly suggest a new or progressing high-risk lesion requiring histological confirmation. The evidence converged on the need for further investigation to guide definitive management.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
